TEL AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic
prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Carotid
Embolic Prevention System (EPS) will be featured in two live case transmissions at the Leipzig Interventional Course (LINC) 2019 to
be held from January 22nd to the 25th at the Trade Fair Leipzig, Hall 2 in Leipzig, Germany. CGuard™ EPS will also be
featured in two panel discussions at the conference.
The two live cases:
Tuesday, 10:57 – 11:22 Live from Bergamo Technical Forum · Room 3
Case 21 – BG 02: male, 64 years (D-V)
Symptomatic left carotid artery disease in a patient with coronary artery disease
Operators: F. Castriota, A. Micari
Tuesday, 16:30 – 18:00 Live from Leipzig Technical Forum · Room 3
Case 27 – LEI 09: female, 56 years (L-K)
Restenosis of the left common carotid artery after TEA
Operators: A. Schmidt, S. Br?unlich
Additional presentations featuring CGuard™ EPS will include:
| What: |
|
Initial clinical study of the new CGuard™ MicroNet® covered carotid-stent:
One size fits all – experimental data and clinical results C. Wissgott, MD, Germany |
| When: |
|
January 22, 10:27 – 10:33 AM Central European Time |
| Where: |
|
Room 3 – Technical Forum |
| |
|
|
| What: |
|
PARADIGM-EXTEND prospective academic trial of CGuard™ MicroNet® covered
self-expandable stent system: Cumulative 3-year clinical and duplex ultrasound evidence for safety, efficacy and durability of
stroke prevention Professor P. Musialek, Poland |
| When: |
|
January 22, 15:05 – 15:10 PM Central European Time |
| Where: |
|
Room 7 – Speaker’s Room |
| |
|
|
| What: |
|
Intermediate results of a prospective randomized study in carotid artery
revascularisation: the Acculink™ stent vs. the mesh covered stent (CGuard™) P. Ignatenko, MD, Russia |
| When: |
|
January 22, 15:15 – 15:20 PM Central European Time |
| Where: |
|
Room 7 – Speaker’s Room |
| |
|
|
| What: |
|
Ad interim results from a prospective real-world multicentre clinical
practice of CAS using the CGuard™ embolic prevention system: the IRONGUARD 2 study W. Mansour, MD, Italy |
| When: |
|
January 22, 15:20 – 15:25 PM Central European Time |
| Where: |
|
Room 7 – Speaker’s Room |
| |
|
|
| What: |
|
Comparative analysis of carotid artery stenting and carotid endarterectomy
in clinical practice Professor Andrey Karpenko, Russia |
| When: |
|
January 22, 15:30 – 15:35 PM Central European Time |
| Where: |
|
Room 7 – Speaker’s Room |
The CGuard™ Carotid Embolic Prevention System will also be featured at the Company’s booth (18c2). InspireMD will be represented
by its management, sales and clinical staff and welcomes all enquiries from clinicians and other interested parties.
LINC is a leading global forum for new methods in the field of vascular medicine. LINC brings together medical professionals
from different specialties around the world who perform endovascular interventions.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal
embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and
peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain
warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Investor Contacts: InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 FREE Email: craigs@inspiremd.com Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 Email: jeremy@lifesciadvisors.com
